Home » Newsletters » BioWorld Science

BioWorld Science

March 2, 2015

View Archived Issues

Otonomy submits NDA to the FDA for AuriPro

Abivax recruits first patient in pivotal phase IIb/III trial of ABX-203

ReveraGen awarded grant to fun development of VBP-15 for Duchenne muscular dystrophy

Rosetta Genomics updates development progress of microRNA-based thyroid neoplasia assay

Phase II trial initiated of Aduro Biotech's GVAX Pancreas and CRS-207 in combination with nivolumab

Amarin and Eddingpharm sign Vascepa agreement for China

Bovine lactoferrin receives two FDA orphan designations

Triphase Accelerator and Sunnybrook Research Institute to collaborate on TRPH-011

Merck Patent discloses new fatty acid synthase inhibitors

German organization patents GRK5 modulators

Gruenenthal patent reports new CRAC inhibitors

New MEK inhibitors patented by Novartis

Scientists at ICGEB disclose anti-dengue virus vaccine

Lenvima now available in U.S.

Inhibition of HIV RNA biogenesis blocks viral replication and avoids viremia rebound

CHMP recommends conditional marketing approval of ceritinib

EMA's CHMP backs approval of Jinarc for rare kidney disease

EMA committee recommends new approval of Vectibix in metastatic colorectal cancer

FDA postpones meeting to discuss a BLA for Celltrion's CT-P13

Combination therapy shows efficiency for HIV/HCV coinfection treatment

Takeda withdraws new European Rienso submission

ENDEAVOR trial shows superiority of Kyprolis over Velcade in relapsed multiple myeloma

EMA accepts MAA for Santen's intravitreal sirolimus for non-infectious uveitis

Ibalizumab receives FDA breakthrough therapy designation

Rare Disease Day 2015: Focus on new means of developing treatments

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...